ArticleEJHaem2025
A Pilot Collaborative Study to Improve the Diagnosis and Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in Senegal: The LYMPHODAK Study.
Article in EJHaem, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Management of diffuse large B-cell lymphoma (DLBCL) in Africa is hampered by limited access to diagnosis and treatment, due to the small number of haematopathologists and lack of clear healthcare pathway. A cooperation between France and Senegal was established to improve diagnosis and provide access to the standard-of-care (R-CHOP) to patients with DLBCL in Dakar. Results: Surgical biopsies were examined in Senegal, then through the Internet Pathology Suite platform, and, when needed, further studied in France. A diagnosis was thus reached for 65/70 biopsies from adults with suspected lymphoma, including 31 DLBCL. A total of 30 patients entered a pilot treatment of six cures of R-CHOP, follow-up and support therapy, between July 2018 and May 2022. The overall response rate was 73% with 57% of complete responses. With a median follow-up of 11.4 months, 24-month overall and progression-free survival rates are of 80% (95% CI 58-91) and 74% (95% CI 50-88). Grade 3/4 haematological toxicity was reported in 20% of the cases. Conclusion: This study brings the proof-of-concept that an accurate DLBCL diagnosis can be obtained in Senegal with organized support and that R-CHOP therapy can be properly conducted, yielding the expected efficacy with acceptable safety. Trial Registration: SEN18/11.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.